Human gut microbiome: hopes, threats and promises - PubMed (original) (raw)
Review
Human gut microbiome: hopes, threats and promises
Patrice D Cani. Gut. 2018 Sep.
Abstract
The microbiome has received increasing attention over the last 15 years. Although gut microbes have been explored for several decades, investigations of the role of microorganisms that reside in the human gut has attracted much attention beyond classical infectious diseases. For example, numerous studies have reported changes in the gut microbiota during not only obesity, diabetes, and liver diseases but also cancer and even neurodegenerative diseases. The human gut microbiota is viewed as a potential source of novel therapeutics. Between 2013 and 2017, the number of publications focusing on the gut microbiota was, remarkably, 12 900, which represents four-fifths of the total number of publications over the last 40 years that investigated this topic. This review discusses recent evidence of the impact of the gut microbiota on metabolic disorders and focus on selected key mechanisms. This review also aims to provide a critical analysis of the current knowledge in this field, identify putative key issues or problems and discuss misinterpretations. The abundance of metagenomic data generated on comparing diseased and healthy subjects can lead to the erroneous claim that a bacterium is causally linked with the protection or the onset of a disease. In fact, environmental factors such as dietary habits, drug treatments, intestinal motility and stool frequency and consistency are all factors that influence the composition of the microbiota and should be considered. The cases of the bacteria Prevotella copri and Akkermansia muciniphila will be discussed as key examples.
Keywords: diabetes mellitus; intestinal microbiology; obesity.
© Article author(s) (or their employer(s) unless otherwise stated in the text of the article) 2018. All rights reserved. No commercial use is permitted unless otherwise expressly granted.
Conflict of interest statement
Competing interests: PDC is inventor on patent applications dealing with the use of A. muciniphila and its components in the treatment of obesity and related disorders. PDC is co-founder of A-Mansia biotech SA.
Figures
Figure 1
Relative sizes of major host cells and their components versus those of bacteria and viruses.
Figure 2
Major mechanisms involved in the crosstalk between microbes and host: impact of metabolism. The balance between healthy and pathological situations (eg, metabolic disorders) is crucial. This is under the tight influence of several factors including the genes, food and drugs. This left part of the figure shows that in healthy situation, the composition of the gut microbiome is associated with a higher mucus layer thickness, the production of antimicrobial signals and different short-chain fatty acids such as butyrate and propionate. Both butyrate and propionate bind to G protein coupled receptors (GPR)-43 and GPR-41 expressed on the enteroendocrine L-cells thereby stimulating the secretion of gut peptides such as glucagon-like peptide-1 (GLP-1) and peptide YY (PYY). This effect contributes to reduce food intake and to improve glucose metabolism. Propionate can also bind to GPR-43 expressed on lymphocytes in order to maintain appropriate immune defence. Butyrate activates peroxisome proliferator-activated receptor-γ (PPAR-γ) leading to beta-oxidation and oxygen consumption, a phenomenon contributing to maintain anaerobic condition in the gut lumen. As depicted on the right part of the figure, during metabolic disorders, changes in the gut microbiome are linked with a lower mucus thickness, decreased antimicrobial defense and butyrate and propionate production. As a consequence, L-cells secrete less gut peptides. The lack of PPAR-γ activation lead to higher oxygen available for the microbiota at the proximity of the mucosa and increases the proliferation of Enterobacteriaceae. The decrease in propionate also contribute to the lower abundance of specific T cells (mucosal-associated invariant T cells (MAIT) and Treg) in the lamina propria of the gut. Altogether, such changes in the microbial environment and metabolites induce a leakage of pathogen associated molecular patterns (PAMPs) such as the lipopolysaccharide (LPS) that are increased in the blood, and trigger low-grade inflammation.
Figure 3
Association between Akkermansia muciniphila and several diseases: what is known? What are the major confounding factors. The picture illustrated different pathological situations where the abundance of the bacteria A. muciniphila has been found to be increased or decreased. It also highlight several confounding factors associated with the modulation of the gut microbiota and eventually the abundance of A. muciniphila according to the health situation and shows the current data for which a proof-of-concept of the link between the disease and the presence of the bacteria has been made.
Similar articles
- [Gut microbiota and immune crosstalk in metabolic disease].
Burcelin R. Burcelin R. Biol Aujourdhui. 2017;211(1):1-18. doi: 10.1051/jbio/2017008. Epub 2017 Jul 6. Biol Aujourdhui. 2017. PMID: 28682223 Review. French. - Akkermansia muciniphila: A promising probiotic against inflammation and metabolic disorders.
Zhao Y, Yang H, Wu P, Yang S, Xue W, Xu B, Zhang S, Tang B, Xu D. Zhao Y, et al. Virulence. 2024 Dec;15(1):2375555. doi: 10.1080/21505594.2024.2375555. Epub 2024 Aug 27. Virulence. 2024. PMID: 39192579 Free PMC article. Review. - Gut Microbiota as a Trigger for Metabolic Inflammation in Obesity and Type 2 Diabetes.
Scheithauer TPM, Rampanelli E, Nieuwdorp M, Vallance BA, Verchere CB, van Raalte DH, Herrema H. Scheithauer TPM, et al. Front Immunol. 2020 Oct 16;11:571731. doi: 10.3389/fimmu.2020.571731. eCollection 2020. Front Immunol. 2020. PMID: 33178196 Free PMC article. Review. - Akkermansia muciniphila: a promising target for the therapy of metabolic syndrome and related diseases.
Zhou JC, Zhang XW. Zhou JC, et al. Chin J Nat Med. 2019 Nov;17(11):835-841. doi: 10.1016/S1875-5364(19)30101-3. Chin J Nat Med. 2019. PMID: 31831130 Review. - The crosstalk between gut microbiota and obesity and related metabolic disorders.
Xu WT, Nie YZ, Yang Z, Lu NH. Xu WT, et al. Future Microbiol. 2016 Jun;11:825-36. doi: 10.2217/fmb-2015-0024. Epub 2016 May 18. Future Microbiol. 2016. PMID: 27192213 Review.
Cited by
- Gut microbiota and their relationship with circulating adipokines in an acute hepatic encephalopathy mouse model induced by surgical bile duct ligation.
Lee B, Jo D, Park J, Kim OY, Song J. Lee B, et al. Heliyon. 2024 Sep 26;10(19):e38534. doi: 10.1016/j.heliyon.2024.e38534. eCollection 2024 Oct 15. Heliyon. 2024. PMID: 39391493 Free PMC article. - Adipokines in the Crosstalk between Adipose Tissues and Other Organs: Implications in Cardiometabolic Diseases.
Hemat Jouy S, Mohan S, Scichilone G, Mostafa A, Mahmoud AM. Hemat Jouy S, et al. Biomedicines. 2024 Sep 19;12(9):2129. doi: 10.3390/biomedicines12092129. Biomedicines. 2024. PMID: 39335642 Free PMC article. Review. - Evidences and perspectives on the association between gut microbiota and sepsis: A bibliometric analysis from 2003 to 2023.
Hu J, Yao Q, Zhao L. Hu J, et al. Heliyon. 2024 Sep 14;10(18):e37921. doi: 10.1016/j.heliyon.2024.e37921. eCollection 2024 Sep 30. Heliyon. 2024. PMID: 39315201 Free PMC article. - Co-Culture of Gut Bacteria and Metabolite Extraction Using Fast Vacuum Filtration and Centrifugation.
Guraka A, Duff R, Waldron J, Tripathi G, Kermanizadeh A. Guraka A, et al. Methods Protoc. 2024 Sep 19;7(5):74. doi: 10.3390/mps7050074. Methods Protoc. 2024. PMID: 39311375 Free PMC article. - A systematic framework for understanding the microbiome in human health and disease: from basic principles to clinical translation.
Ma Z, Zuo T, Frey N, Rangrez AY. Ma Z, et al. Signal Transduct Target Ther. 2024 Sep 23;9(1):237. doi: 10.1038/s41392-024-01946-6. Signal Transduct Target Ther. 2024. PMID: 39307902 Free PMC article. Review.
References
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical